Abstract
Despite significant advancements in the treatment options for idiopathic pulmonary fibrosis (IPF), the disease remains aggressive and incurable. This viewpoint summarizes the discovery of a neutral, potent, and selective lysophosphatidic acid receptor 1 antagonist for the treatment of IPF. The lead optimization without the cocrystal structure guidance is worth it to highlight.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call